These endeavors elucidated an augmented GLIPR2 expression in BLCA, BRCA, cholangiocarcinoma (CHOL), amongst others, in contrast to a diminution in breast, colon, ovarian cancers, among others (Figures 2E, F). The gene discussed is GLIPR2; the disease is ovarian carcinoma.